• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

[基础知识] 给ICB免疫减毒增效的 药物(十九)--肌苷、β-葡聚糖

[复制链接]
5046 0 自学自救 发表于 2025-4-3 17:11:20 |

马上注册,结交更多好友,享用更多功能,让你轻松玩转社区。

您需要 登录 才可以下载或查看,没有账号?立即注册

x
第一部分 肌苷$ |) Y8 Z) p" U

! e( z+ K" F6 j& K5 z$ h
# E* l6 X& o! ?- \7 O% Z4 g《Inosine enhances the efficacy of immune-checkpoint inhibitors in advanced solid tumors: A randomized, controlled, Phase 2 study》 一文介绍了一项前瞻性随机对照二期临床试验:
( [0 N7 o# y* n, m' b
8 E9 k0 c8 G( ^: V- U1、入组患者:172名晚期实体瘤患者,分为 ICB免疫治疗+肌苷组和 ICB免疫治疗组不联合肌苷(该组部分患者联合了化疗或者靶向)两组,每组86名患者。1 o: w0 s1 ~) y7 v4 E0 Y+ l
. m' a+ b/ z% d/ k
2、肌苷用法:口服肌苷片,每天三次,每次0.2克。( h* E0 x: J1 C' a* Y0 `/ l0 w

1 R/ s7 ]  ?: W! h$ L+ P3、试验结果:肌苷组和非肌苷组中位PFS (95% CI)分别为7.00(5.31-8.69)和4.40(3.10-5.70)个月(风险比[HR]0.63;95%置信区间为0.44–0.90,p= 0.011),肌苷组PFS提高有统计学意义。ORR分别为26.7%和15.1%(p= 0.061),肌苷组ORR有改善。非肌苷组中位OS为29.67个月(95% CI 17.40–41.94),肌苷组中位OS尚未达到。
! K" i% d; J. w; G4 z1 p ( T; U4 k& O" D4 U. L4 z* I; E
肌苷组和非肌苷组分别有25名(29%)和31名(36%)患者出现3级和4级不良反应,肌苷组的不良反应趋于减少。
! Y* f) q4 v& Y9 e- |! B - f6 X4 Q3 P. B1 v
$ m9 n! ^) E' R+ q

$ d5 x; ?6 \7 {第二部分 β-葡聚糖
3 Q, H% E6 o# Q- i: m* q - a" i2 I/ @! Q. e& T# L1 H1 \

: C+ L! K/ ^7 @《β-glucan combined with Envafolimab and Endostar as immune rechallenge for metastatic non-small cell lung cancer》一文介绍了一项前瞻性随机对照二期临床试验,β-葡聚糖+pd-1i 恩沃利 + 抗血管生成药物治疗先前pd-1i治疗失败的非小细胞肺癌。
6 W  |3 Y' d( I" ?2 t( z) {3 ^! O
- R6 d! @' A! u$ n2 n; @# `1、入组患者:23名晚期非小细胞肺癌患者,这些患者之前用pd-1i治疗都已经失败。
" q0 S" N% r; m& A+ T
& G: a) B  X2 z# ^2 V# p' Q6 A2、β-葡聚糖用法:每天两次,每次500毫克。' s, k7 f8 p2 T$ B
( {+ d8 H4 ]" O. ~9 A( c
3、试验结果:ORR 21.7%,DCR 73.9%.,PFS 4.3个月,OS 8.9个月。PD-L1阳性和阴性亚组之间的mPFS有显著差异(6.3个月对2.3个月,p = 0.002)。/ s0 V7 k0 N: [" ]" v; P8 T( M; w
) e' z$ O1 |* {7 G7 u( b6 V
52.2%的患者发生了治疗相关的不良事件。最常见的原因是甲状腺功能减退(26.1%)和疲劳(26.1%)。报告了2例(8.7%)3级不良事件。未观察到与死亡相关的不良反应。3 |7 M, T2 X- F6 E& c- h" i

6 R: k  i# u, u" U# J3 @蛋白质组学分析显示CASP-8、ARG1、MMP12、CD28和CXCL5的水平与对治疗的抗性相关,而CD40-L和EGF的水平与有利的反应相关。5 i/ N, c( j5 |

2 u1 N  X  N6 U  [1 J* T(因为患者都是之前用pd-1i都已经失败的患者,所以ORR 21.7%,DCR 73.9% 还是很不错的)
. y% h5 b' C5 N. ~) A9 A
0 Y  Q3 k3 j! s, Y
2 q2 ]. N) a3 ]I 《Inosine enhances the efficacy of immune-checkpoint inhibitors in advanced solid tumors: A randomized, controlled, Phase 2 study》7 s- p3 U  K6 L4 k6 v* Y$ ?6 {

, c& E( r' B* R# X# {% v2 BBackground: This study aimed to evaluate whether inosine enhances the efficacy of immune-checkpoint inhibitors in human malignant solid tumors.
, R1 ~* M# D7 ?8 S( |( a0 f7 U
0 q( T  v5 O1 R4 m. [( Z9 A( W/ E: SMethods: This single-center, prospective, randomized, open-label study was conducted, from January 2021 to December 2022, in Beijing Friendship Hospital, Capital Medical University, and participants were randomly assigned (1:1) to either the inosine (trial) or non-inosine (control) group that received inosine (dosage: 0.2 g, three times/day) + PD-1/PD-L1 inhibitor or only PD-1/PD-L1 inhibitor ± targeted ± chemotherapy, respectively. Efficacy was assessed every 6 weeks (i.e., after every two-three treatment cycles). The primary endpoint was the objective response rate (ORR); the secondary endpoints were disease control rate, overall survival (OS), and progression-free survival (PFS). The trial was registered at ClinicalTrials.gov (NCT05809336).& R4 v9 w: o: g, \3 @/ P& c

+ z: d% l8 A1 r, C7 dResults: Among the 172 participants with advanced malignant solid tumors, 86 each were assigned to the inosine and non-inosine groups, wherein the median PFS (95% CI) was 7.00 (5.31-8.69) and 4.40 (3.10-5.70) months, respectively (hazard ratio [HR] 0.63; 95% CI 0.44-0.90, p = 0.011), and the ORR was 26.7% and 15.1%, respectively (p = 0.061). In the inosine and non-inosine groups, the median OS was not reached and was 29.67 (95% CI 17.40-41.94) months, respectively (HR 1.05 [95% CI 0.59-1.84], p = 0.874). Compared with the non-inosine group, the median PFS and ORR of the inosine group were significantly prolonged and improved in the multiple exploratory subgroup analyses. The safety analysis showed that Grades 3 and 4 adverse reactions occurred in 25 (29%) and 31 (36%) patients in the inosine and non-inosine groups, respectively, and tended to decrease in the inosine group compared with the non-inosine group.! z6 W6 ~/ G  _/ |
& P$ J! r6 _* Q0 @( o0 r
Conclusion: Inosine had a tendency to enhance the efficacy of immune-checkpoint inhibitors and reduced immunotherapy-related adverse reactions.3 Z' A/ v2 ^$ Y) a1 A
( V+ c6 W& ?  e* r
& {, Y3 a9 Q6 u. f$ Y5 D8 x3 |3 D

# W( @6 K- w5 D. |II 《β-glucan combined with Envafolimab and Endostar as immune rechallenge for metastatic non-small cell lung cancer》
! U+ C2 T+ H0 F: E1 p8 m8 i / ^4 P. d, ^+ Y
Background: Immune checkpoint inhibitor rechallenge has emerged as a prominent study area in non-small cell lung cancer (NSCLC). β-glucan was reported to reverse resistance to anti-PD-1/PD-L1 inhibitors by regulating the tumor microenvironment. In this self-initiated clinical trial (ChiCTR2100054796), NSCLC participants who have previously failed anti-PD-1 therapy received β-glucan (500 mg, bid, d1-21), Envafolimab (300 mg, d1) and Endostar (210 mg, civ72h) every 3 weeks until disease progression or unacceptable toxicity. The clinical efficacy and adverse events were observed, while serum samples were collected for proteomic analysis.8 e$ ]. x- [) t6 g* x
! Z( L' G7 D9 e# C" q
Results: Twenty Three patients were enrolled from January 2022 to March 2023 (median age, 65 years; male, n = 18 [78.3%]; squamous NSCLC, n = 9 [39.1%]; mutant type, n = 13 [56.5%]). The overall response rate (ORR) was 21.7% and disease control rate (DCR) was 73.9%. Median progression-free survival (mPFS) and median overall survival (mOS) was 4.3 months [95% CI: 2.0-6.6] and 9.8 months [95% CI: 7.2-12.4], respectively. The mPFS between PD-L1 positive and negative subgroup has significant difference (6.3 months vs. 2.3 months, p = 0.002). Treatment-related adverse events (TRAEs) occurred in 52.2% of patients. The most common TRAEs were hypothyroidism (26.1%) and fatigue (26.1%). 2 (8.7%) grade 3 adverse events were reported. No adverse reaction related deaths have been observed. Proteomic analysis revealed that the levels of CASP-8, ARG1, MMP12, CD28 and CXCL5 correlated with resistance to the treatment while the levels of CD40-L and EGF related to the favorable response.. E  I4 R, K- m! p
  o' n5 N5 S4 X
Conclusion: β-glucan combined with Envafolimab and Endostar has considerable efficacy and safety for immune rechallenge in metastatic NSCLC patients who failed of anti-PD-1 treatment previously, especially for PD-L1 positive patients.

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表